-
1Academic Journal
Συγγραφείς: O. V. Zhukova, A. L. Khokhlov, О. В. Жукова, А. Л. Хохлов
Πηγή: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 14, No 1 (2021); 16-27 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 14, No 1 (2021); 16-27 ; 2070-4933 ; 2070-4909
Θεματικοί όροι: бета-распределение клинических исходов, dexamethasone, tocilizumab, attribute-based statistics, clinical constituent of therapy, economic constituent of therapy, Markov’s modeling, inter-drug interaction, beta-distribution of clinical outcomes, дексаметазон, тоцилизумаб, атрибутивная статистика, клиническая составляющая терапии, экономическая составляющая терапии, марковское моделирование, межлекарственные взаимодействия
Περιγραφή αρχείου: application/pdf
Relation: https://www.pharmacoeconomics.ru/jour/article/view/483/358; Huang X., Wei F., Hu L., Wen L., Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020; 23 (4): 268–71. https://doi.org/10.34172/aim.2020.09.; Zhai P., Ding Y., Wu X., et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020; 55 (5): 105955. https://doi.org/10.1016/j.ijantimicag.2020.105955.; Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19). Outbreak in China: summary of a report of cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–42. https://doi.org/10.1001/jama.2020.2648.; Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med. 2020; 8 (5): 475–81. https://doi.org/10.1016/S2213-2600(20)30079-5.; Макацария А.Д., Григорьева К.Н., Мингалимов М.А. и др. Коронавирусная болезнь (COVID-19) и синдром диссеминированного внутрисосудистого свертывания крови. Акушерство, гинекология и репродукция. 2020; 14 (2): 123–31. https://doi.org/10.17749/2313-7347.132.; Хизроева Д.Х., Макацария А.Д., Бицадзе В.О. и др. Лабораторный мониторинг COVID-19 и значение определения маркеров коагулопатии. Акушерство, гинекология и репродукция. 2020; 14 (2): 132–47. https://doi.org/10.17749/2313-7347.141.; Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020; 80 (6): 607–13. https://doi.org/10.1016/j.jinf.2020.03.037.; Cellina M., Orsi M., Bombaci F., et al. Favorable changes of CT findings in a patient with COVID-19 nia after treatment with tocilizumab. Diagn Interv Imaging. 2020; 101 (5): 323–4. https://doi.org/10.1016/j.diii.2020.03.010.; Xu X., Han M., Li T., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117 (20): 10970–5. https://doi.org/10.1073/pnas.2005615117.; Radbel J., Narayanan N., Bhatt P.J. Use of tocilizumab for COVID-19induced cytokine release syndrome: a cautionary case report. Chest. 2020; 158 (1): e15–9. https://doi.org/10.1016/j.chest.2020.04.024.; Luo P., Liu Y., Qiu L., et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020; 92 (7): 814–8. https://doi.org/10.1002/jmv.25801.; Biggioggero M., Crotti C., Becciolini A., Favalli E.G. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2018; 13: 57–70. https://doi.org/10.2147/DDDT.S150580.; Tanaka T., Narazaki M., Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016; 8 (8): 959–70. https://doi.org/10.2217/imt-2016-0020.; Horby P., Shen Lim W., et al. Effect of Dexamethasone in hospitalized patients with COVID-19: preliminary report. https://doi.org/10.1101/2020.06.22.20137273.; Barnes P.J. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006; 148 (3): 245–54. https://doi.org/10.1038/sj.bjp.0706736.; Kumar K., Hinks T. S., Singanayagam A. Treatment of COVID-19exacerbated asthma: should systemic corticosteroids be used? Ame J Physiol Lung Cell Mol Physiol. 2020; 318 (6): L1244–7. https://doi.org/10.1152/ajplung.00144.2020.; Hui D. S., Lee N., Chan P.K. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res. 2013; 98 (3): 410–46. https://doi.org/10.1016/j.antiviral.2013.03.019.; De Wit E., Van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14 (8): 523–34. https://doi.org/10.1038/nrmicro.2016.81.; Auyeung T.W., Lee J.S., Lai W.K., et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005; 51 (2): 98–102. https://doi.org/10.1016/j.jinf.2004.09.008.; Ho J.C., Ooi G.C., Mok T.Y., et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003; 168 (12): 1449–56. https://doi.org/10.1164/rccm.200306-766OC.; Yam L.Y., Lau A.C., Lai F.Y., et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007; 54(1): 28–39. https://doi.org/10.1016/j.jinf.2006.01.005.; Сhen R.C, Tang X.P., Tan S.Y., et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129 (6): 1441–52. https://doi.org/10.1378/chest.129.6.1441.; Corticosteroids for COVID-19. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (дата обращения 12.03.2021).; Somers E.C., Eschenauer G.A., Troost J. P., et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020; ciaa954. https://doi.org/10.1093/cid/ciaa954.; Annane D., Bellissant E., Bollaert P.E., et al. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. 2015; 2015 (12): CD002243. https://doi.org/10.1002/14651858.CD002243.pub3.; https://www.pharmacoeconomics.ru/jour/article/view/483